1. Home
  2. PMO vs OBIO Comparison

PMO vs OBIO Comparison

Compare PMO & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Municipal Opportunities Trust

PMO

Putnam Municipal Opportunities Trust

HOLD

Current Price

$10.26

Market Cap

282.5M

Sector

Finance

ML Signal

HOLD

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$5.07

Market Cap

253.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMO
OBIO
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.5M
253.9M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PMO
OBIO
Price
$10.26
$5.07
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.25
AVG Volume (30 Days)
58.6K
301.3K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
4.10%
N/A
EPS Growth
N/A
33.13
EPS
N/A
N/A
Revenue
N/A
$33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.43
P/E Ratio
$25.02
N/A
Revenue Growth
N/A
1169.22
52 Week Low
$9.80
$2.20
52 Week High
$10.87
$5.78

Technical Indicators

Market Signals
Indicator
PMO
OBIO
Relative Strength Index (RSI) 42.33 58.82
Support Level $10.22 $3.72
Resistance Level $10.58 $5.42
Average True Range (ATR) 0.12 0.31
MACD -0.01 -0.01
Stochastic Oscillator 15.56 54.43

Price Performance

Historical Comparison
PMO
OBIO

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, leases, local, Housing, education, and Others.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: